跳至主要内容
临床试验/NCT00233623
NCT00233623撤回2 期

A Randomised, Non-Comparative, Multicentre, Phase II, Parallel-Group Trial Of ZD1839 (Iressa™) In Combination With 5 Fluorouracil, Leucovorin And Cpt-11 (Irinotecan) In Patients With Metastatic Colorectal Cancer

AstraZeneca13 个研究点 分布在 1 个国家目标入组 190 人开始时间: 2004年7月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
撤回
发起方
AstraZeneca
入组人数
190
试验地点
13
主要终点
Time to progression (6 months after Last patient in)

研究概览

简要总结

The aim of the study is to determine if Iressa added to chemotherapy with Irinotecan, 5Fluorouracil and Leucovorin can prolong the period of time without any disease worsening (Time to Progression) in patients with metastatic colorectal cancer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically confirmed metastatic colorectal cancer
  • Presence of measurable metastases
  • No previous treatment for metastatic cancer

排除标准

  • No presence of Central Nervous System metastases
  • No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
  • Any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)

结局指标

主要结局

Time to progression (6 months after Last patient in)

次要结局

  • Objective Response Rate, Duration of Response, Disease control rate, Overall Survival, (6 months after Last patient in)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (13)

Loading locations...

相似试验